オプションチェーンは、Daiichi Sankyo Coの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Daiichi Sankyo Coの市場センチメントを評価します。.

Daiichi Sankyo Co (OTC:DSNKY) 株価情報, オプションチェーン

DAIICHI SANKYO

Daiichi Sankyo Co

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

DAIICHI SANKYO S/ADR by Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co Ltd

AstraZeneca gets FDA breakthrough therapy status for Dato-DXd

AstraZeneca, Daiichi pull EU marketing application for lung cancer drug, Dato-DXd

Here are Morgan Stanley's key oncology catalysts for 2025

High Expectations And Data Disappointments Have Driven Daiichi Sankyo Lower

AstraZeneca, Daiichi Sankyo antibody-drug conjugate Dato-DXd gains FDA nod

Daiichi Sankyo appoints Hiroyuki Okuzawa as CEO

AstraZeneca, Daiichi win EU backing for breast cancer drug Dato-DXd

Daiichi Sankyo Company, Limited 2024 Q3 - Results - Earnings Call Presentation

Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript

Daiichi Sankyo sees ENHERTU sales reaching ¥539.9B in FY2024 amid oncology momentum

AKESF

ARVN

AZNCF

BNTX

DSKYF

DSNKY

GILD

MRNA

RCUS

REGN

RHHBY

SMMT

Press Releases

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

CGEN

GRAL

TYO:4568

Comments

Daiichi Sankyo Co

Daiichi Sankyo Co (DSNKY) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル